BACKGROUND: The choices of treatment for patients with extensive tumors of the femur include total femur megaprosthesis or large allograft-prosthetic composites. Previous reports suggest variable survival ranging from 60-70% at 1 to 2 years. However, these studies described earlier prostheses and techniques. QUESTIONS/PURPOSES: To confirm previous reports we determined (1) risk of local recurrence; (2) overall survivorship; and (3) function in patients with total femur reconstructions for tumors. METHODS: We retrospectively reviewed 23 patients with total femur megaprostheses implanted between 1987 and 2006 after resection of bone tumors. Two patients lost at followup were excluded; the remaining 21 included 15 males and six females with a mean age of 21 years. The mean followup was 48 months (range, 1 month 17 years). Function was assessed according to the MSTS System II. RESULTS: No patient developed a local recurrence during followup. At last followup, six patients were continuously disease-free at a mean of 148 months, one patient had no evidence of disease after treatment of a recurrence, one patient was alive with disease, and 13 patients died of their disease at a mean time of 17 months. In 15 patients evaluated with the MSTS score, the mean score was 66%; four patients had over 75%, eight from 51% to 75%, three from 26% to 50%. Four patients (19%) had complications requiring further surgery in absence of trauma. A fifth patient had a posttraumatic periprosthetic fracture. CONCLUSIONS: A total femur prosthesis allows a limb-preserving procedure in tumors with extensive femoral involvement or in the presence of a skip lesion along the femur. The prognosis of these tumors is poor, but this reconstruction provides function with a relatively low rate of major complications.
BACKGROUND: The choices of treatment for patients with extensive tumors of the femur include total femur megaprosthesis or large allograft-prosthetic composites. Previous reports suggest variable survival ranging from 60-70% at 1 to 2 years. However, these studies described earlier prostheses and techniques. QUESTIONS/PURPOSES: To confirm previous reports we determined (1) risk of local recurrence; (2) overall survivorship; and (3) function in patients with total femur reconstructions for tumors. METHODS: We retrospectively reviewed 23 patients with total femur megaprostheses implanted between 1987 and 2006 after resection of bone tumors. Two patients lost at followup were excluded; the remaining 21 included 15 males and six females with a mean age of 21 years. The mean followup was 48 months (range, 1 month 17 years). Function was assessed according to the MSTS System II. RESULTS: No patient developed a local recurrence during followup. At last followup, six patients were continuously disease-free at a mean of 148 months, one patient had no evidence of disease after treatment of a recurrence, one patient was alive with disease, and 13 patients died of their disease at a mean time of 17 months. In 15 patients evaluated with the MSTS score, the mean score was 66%; four patients had over 75%, eight from 51% to 75%, three from 26% to 50%. Four patients (19%) had complications requiring further surgery in absence of trauma. A fifth patient had a posttraumatic periprosthetic fracture. CONCLUSIONS: A total femur prosthesis allows a limb-preserving procedure in tumors with extensive femoral involvement or in the presence of a skip lesion along the femur. The prognosis of these tumors is poor, but this reconstruction provides function with a relatively low rate of major complications.
Authors: Kaveh R Sajadi; Robert K Heck; Michael D Neel; Bhaskar N Rao; Najat Daw; Carlos Rodriguez-Galindo; Fredric A Hoffer; G Scott Stacy; Terrance D Peabody; Michael A Simon Journal: Clin Orthop Relat Res Date: 2004-09 Impact factor: 4.176
Authors: G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban Journal: Cancer Date: 1982-03-15 Impact factor: 6.860
Authors: Florian Sevelda; Reinhard Schuh; Jochen Gerhard Hofstaetter; Martina Schinhan; Reinhard Windhager; Philipp Theodor Funovics Journal: Clin Orthop Relat Res Date: 2015-04-02 Impact factor: 4.176
Authors: Jelle Gorter; Joris J W Ploegmakers; Bas L E F Ten Have; Hendrik W B Schreuder; Paul C Jutte Journal: Int Orthop Date: 2017-03-30 Impact factor: 3.075
Authors: Kevin B Jones; Anthony M Griffin; Coonoor R Chandrasekar; David Biau; Antoine Babinet; Benjamin Deheshi; Robert S Bell; Robert J Grimer; Jay S Wunder; Peter C Ferguson Journal: J Surg Oncol Date: 2011-06-21 Impact factor: 3.454